Related Experiment Video
Updated: May 14, 2025
09:01
Minimally Invasive Endoscopic Intracerebral Hemorrhage Evacuation
Published on: October 15, 2021
7.4K
Deferoxamine for Spontaneous Intracranial Hemorrhage: A Pilot Study on Neurological and Radiological Outcomes.
Mohammad Shirani1, Masoud Sohrabiasl2, Ali Meshkini2
1Department of Neurosurgery, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Korean Journal of Neurotrauma
|May 12, 2025
Summary
Deferoxamine improved neurological and radiological outcomes in patients with spontaneous intracranial hemorrhage (ICH). This iron chelation therapy reduced hematoma and edema volumes, and decreased mortality rates in the short term.
Area of Science:
- Neurology
- Neurosurgery
- Pharmacology
Background:
- Spontaneous intracranial hemorrhage (ICH) is a severe condition with high mortality.
- Iron accumulation post-ICH exacerbates secondary brain injury.
- Deferoxamine, an iron chelator, is being investigated for its therapeutic potential in ICH.
Purpose of the Study:
- To evaluate the therapeutic efficacy of deferoxamine in patients with spontaneous ICH.
- To assess the impact of deferoxamine on neurological and radiological outcomes.
Main Methods:
- A double-blind, randomized controlled trial involving 42 participants with spontaneous ICH.
- Participants received either deferoxamine (7.5 mg/kg/hr IV for 3 days) or placebo, alongside routine care.
- Outcomes measured included hematoma/edema volume, Glasgow Coma Scale (GCS) scores, and mortality.
Main Results:
- Significant improvement in GCS scores observed up to day four in the deferoxamine group.
- Reduced hematoma and edema volumes in the deferoxamine group compared to placebo.
- Lower rates of prolonged hospital stay, intubation, and mortality with deferoxamine treatment.
Conclusions:
- Deferoxamine administration shows short-term benefits in improving neurological and radiological parameters in ICH patients.
- Iron chelation with deferoxamine may mitigate secondary brain injury following ICH.
